biohacking$bioLLM CA: TBA

database / immune

Vancomycin

approved immune immune sequence not characterised
ClClOOOOOOOOOOOOOOOOOOOOOOOONNNNNNNNNHHHHHHHHHHHHHHHHHHHHH
101 heavy atoms · 185 bonds · drag to pan, scroll to zoom C66O24N9Cl2

Skeletal structure drawn from the computed atomic coordinates in PubChem CID 14969. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.

A glycopeptide assembled non-ribosomally; its cross-linked aromatic core is not a linear peptide sequence.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formulaC66H75Cl2N9O24
molecular weight1449.2 Da (PubChem)
computed backbone massnot characterised
lengthnot characterised
net charge (pH 7.4)not characterised
mean hydropathynot characterised
half-lifenot characterised
delivery routeintravenous, oral
PubChem CID14969
PDBnot characterised
UniProt parentnot characterised

Mechanism

Binds the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking cell-wall cross-linking.

Reported targets: peptidoglycan D-Ala-D-Ala

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcomewhere it appears
bactericidal activity against Gram-positive organismsDiscrepancies in Vancomycin Clearance Estimation Among Renal Function Models… Basic & clinical pharmacology & toxicology 2026

Registered trials

Records from ClinicalTrials.gov. Listed for reference — this project sponsors no trial and is not involved in any of them.
NCTtitlestatusphase
NCT00991185Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in ChildrenCOMPLETED
NCT00295178Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or ErysipeCOMPLETEDPHASE4
NCT03268122Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial TransmissCOMPLETEDNA
NCT01496794Endophthalmitis CulturesTERMINATED
NCT06272994Swab Testing to Optimize Pneumonia Treatment With Empiric VancomycinCOMPLETEDNA

Literature (8)

Discrepancies in Vancomycin Clearance Estimation Among Renal Function Models in Patients With Low Serum Creatinine Levels: A Pilot Study — Basic & clinical pharmacology & toxicology 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42609167 · DOI 10.1111/bcpt.70287

Acute Kidney Injury During Vancomycin Treatment in Adult Patients With Haematologic Malignancies: A Multicentre Retrospective Study — Basic & clinical pharmacology & toxicology 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42633950 · DOI 10.1111/bcpt.70297

Assessing Vancomycin-Formyl Peptide Conjugate Binding to the Surface of Resistant Staphylococcus aureus via Flow Cytometry — Chembiochem : a European journal of chemical biology 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42555848 · DOI 10.1002/cbic.70495

Evaluation of Vancomycin Dosing Practices in Critically Ill Patients Receiving Accelerated Venovenous Hemofiltration — Journal of clinical pharmacology 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42212507 · DOI 10.1002/jcph.70176

Vancomycin-stressed <i>Staphylococcus aureus</i> extracellular vesicles hijack macrophage autophagy to enhance bacterial intracellular survival — Autophagy 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42437365 · DOI 10.1080/15548627.2026.2702841

Narasin used as a feed additive in conventional rearing of broilers can co-select for vancomycin-resistant Enterococcus faecium through the NarAB ionophore resistance mechanisms — The Journal of antimicrobial chemotherapy 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42639740 · DOI 10.1093/jac/dkag253

Vancomycin-Mediated Binding of DNA Origami Nanostructures to Gram-Positive and Gram-Negative Bacteria — Chembiochem : a European journal of chemical biology 2026

DNA origami nanostructures (DONs) have promising applications in biomedicine and biosensing, which often require their efficient binding to target cells. By immobilizing the glycopeptide antibiotic vancomycin on DONs, DON binding to Gram-positive and Gram-negative bacteria can be facilitated. Here, we investigate how this multivalent binding is affected by the number and arrangement of the vancomycin modifications on two-dimensional DONs. We find that for both Gram-positive Bacillus subtilis and Gram-negative Escherichia coli, binding increases with the number of vancomycin modifications per DON. In general, binding to E. coli is stronger than to B. subtilis, which may be attributed to differences in the architectures of the cell envelopes. Interestingly, for both bacteria, the total number of vancomycin modifications appears to be more important than their arrangement, as DONs with 18 v…

open access ↗ · PMID 42376742 · DOI 10.1002/cbic.70436

The efflux pump QacA mediates the transition to vancomycin heteroresistance in sequence type 5 methicillin-resistant <i>Staphylococcus aureus</i> via membrane lipid reprogramming — Emerging microbes & infections 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42504701 · DOI 10.1080/22221751.2026.2698241

Related

KPV

immune · 8 citations

Tuftsin

immune · 8 citations

Thymosin α1

immune · 8 citations

LL-37

immune · 8 citations

Human β-defensin 2

immune · 8 citations

Thymulin

immune · 8 citations